v3.26.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development $ 114 $ 7,627
General and administrative 5,425 3,309
Acquired in-process research and development 22,180 0
Loss from operations (27,719) (10,936)
Other income (expense), net:    
Interest expense 0 (161)
Interest income and other income (expense), net 23 237
Total other income (expense), net 23 76
Provision for income taxes 0 0
Net loss $ (27,696) $ (10,860)
Net loss per share of common stock and pre-funded warrants, basic [1] $ (2.53) $ (3.16)
Net loss per share of common stock and pre-funded warrants, diluted [1] $ (2.53) $ (3.16)
Weighted-average shares of common stock and pre-funded warrants outstanding, basic [1] 10,931,593 3,437,671
Weighted-average shares of common stock and pre-funded warrants outstanding, diluted [1] 10,931,593 3,437,671
[1] Results, including shares of common stock, have been adjusted to reflect the one-for-thirteen stock split effected in April 2025. See Note 1, Organization and Description of the Business, for details.